MEN1703

DRUG2 trials

Sponsors

Menarini Group, Ryvu Therapeutics SA

Conditions

Acute Myeloid LeukemiaNon-Hodgkin Lymphoma, B-cell

Phase 1

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

CompletedNCT03008187

Menarini GroupAcute Myeloid Leukemia

Start: 2017-03-10End: 2023-04-13Updated: 2025-04-29

Phase 2

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

RecruitingNCT06534437

Ryvu Therapeutics SANon-Hodgkin Lymphoma, B-cell

Start: 2024-12-05End: 2026-12-01Target: 178Updated: 2026-09-18

Related Papers

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Blood2025-11-03

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.

2025-10-24

PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Blood2022-11-15

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with <i>IDH1/2</i>-mutated acute myeloid leukemia: The DIAMOND-01 trial.

Journal of Clinical Oncology2022-06-012 citations

P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.

HemaSphere2022-06-01

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood2021-11-053 citations

Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

Journal of Clinical Oncology2021-05-203 citations

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Blood2020-11-04

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Blood2019-11-131 citations

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Blood2019-11-13

CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.

Journal of Clinical Oncology2019-05-20